BPTH — Bio-Path Holdings, Inc.
$0.00
+$0.00 (+0.00%)
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge.
Market Cap
$15089.00
Forward P/E
-0.0x
52-Week Range
N/A
BPTH Price History
Revenue vs. Net Income
$0
Revenue · FY2024
Annual. Net margin is shown under each year.
Free Cash Flow
-$10.6M
FCF · FY2024
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-2039.5%
ROCE · FY2024
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.0x
Assets ÷ liabilities · FY2024
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+402.3%
Dilution · FY2024
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
